FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020180938> ?p ?o ?g. }

• W2020180938 endingPage "339" @default.
• W2020180938 startingPage "332" @default.
• W2020180938 abstract "Purpose In 2007, we published our initial experience in treating inoperable non-small-cell lung cancer (NSCLC) with intensity-modulated radiation therapy (IMRT). The current report is an update of that experience with long-term follow-up. Methods and Materials Patients in this retrospective review were 165 patients who began definitive radiotherapy, with or without chemotherapy, for newly diagnosed, pathologically confirmed NSCLC to a dose of ≥60 Gy from 2005 to 2006. Early and late toxicities assessed included treatment-related pneumonitis (TRP), pulmonary fibrosis, esophagitis, and esophageal stricture, scored mainly according to the Common Terminology Criteria for Adverse Events 3.0. Other variables monitored were radiation-associated dermatitis and changes in body weight and Karnofsky performance status. The Kaplan-Meier method was used to compute survival and freedom from radiation-related acute and late toxicities as a function of time. Results Most patients (89%) had Stage III to IV disease. The median radiation dose was 66 Gy given in 33 fractions (range, 60–76 Gy, 1.8–2.3 Gy per fraction). Median overall survival time was 1.8 years; the 2-year and 3-year overall survival rates were 46% and 30%. Rates of Grade ≥3 maximum TRP (TRPmax) were 11% at 6 months and 14% at 12 months. At 18 months, 86% of patients had developed Grade ≥1 maximum pulmonary fibrosis (pulmonary fibrosismax) and 7% Grade ≥2 pulmonary fibrosismax. The median times to maximum esophagitis (esophagitismax) were 3 weeks (range, 1–13 weeks) for Grade 2 and 6 weeks (range, 3–13 weeks) for Grade 3. A higher percentage of patients who experienced Grade 3 esophagitismax later developed Grade 2 to 3 esophageal stricture. Conclusions In our experience, using IMRT to treat NSCLC leads to low rates of pulmonary and esophageal toxicity, and favorable clinical outcomes in terms of survival. In 2007, we published our initial experience in treating inoperable non-small-cell lung cancer (NSCLC) with intensity-modulated radiation therapy (IMRT). The current report is an update of that experience with long-term follow-up. Patients in this retrospective review were 165 patients who began definitive radiotherapy, with or without chemotherapy, for newly diagnosed, pathologically confirmed NSCLC to a dose of ≥60 Gy from 2005 to 2006. Early and late toxicities assessed included treatment-related pneumonitis (TRP), pulmonary fibrosis, esophagitis, and esophageal stricture, scored mainly according to the Common Terminology Criteria for Adverse Events 3.0. Other variables monitored were radiation-associated dermatitis and changes in body weight and Karnofsky performance status. The Kaplan-Meier method was used to compute survival and freedom from radiation-related acute and late toxicities as a function of time. Most patients (89%) had Stage III to IV disease. The median radiation dose was 66 Gy given in 33 fractions (range, 60–76 Gy, 1.8–2.3 Gy per fraction). Median overall survival time was 1.8 years; the 2-year and 3-year overall survival rates were 46% and 30%. Rates of Grade ≥3 maximum TRP (TRPmax) were 11% at 6 months and 14% at 12 months. At 18 months, 86% of patients had developed Grade ≥1 maximum pulmonary fibrosis (pulmonary fibrosismax) and 7% Grade ≥2 pulmonary fibrosismax. The median times to maximum esophagitis (esophagitismax) were 3 weeks (range, 1–13 weeks) for Grade 2 and 6 weeks (range, 3–13 weeks) for Grade 3. A higher percentage of patients who experienced Grade 3 esophagitismax later developed Grade 2 to 3 esophageal stricture. In our experience, using IMRT to treat NSCLC leads to low rates of pulmonary and esophageal toxicity, and favorable clinical outcomes in terms of survival." @default.
• W2020180938 created "2016-06-24" @default.
• W2020180938 creator A5012796164 @default.
• W2020180938 creator A5013581376 @default.
• W2020180938 creator A5028786618 @default.
• W2020180938 creator A5034765756 @default.
• W2020180938 creator A5041943880 @default.
• W2020180938 creator A5055965589 @default.
• W2020180938 creator A5058839299 @default.
• W2020180938 creator A5060222943 @default.
• W2020180938 creator A5064028169 @default.
• W2020180938 creator A5064307215 @default.
• W2020180938 creator A5072460259 @default.
• W2020180938 creator A5077763767 @default.
• W2020180938 creator A5085700191 @default.
• W2020180938 creator A5086483620 @default.
• W2020180938 creator A5089211608 @default.
• W2020180938 date "2012-05-01" @default.
• W2020180938 modified "2023-10-12" @default.
• W2020180938 title "Long-Term Clinical Outcome of Intensity-Modulated Radiotherapy for Inoperable Non-Small Cell Lung Cancer: The MD Anderson Experience" @default.
• W2020180938 cites W1991815527 @default.
• W2020180938 cites W2004921695 @default.
• W2020180938 cites W2019570186 @default.
• W2020180938 cites W2035704169 @default.
• W2020180938 cites W2041180978 @default.
• W2020180938 cites W2042205682 @default.
• W2020180938 cites W2044307910 @default.
• W2020180938 cites W2058185386 @default.
• W2020180938 cites W2096786305 @default.
• W2020180938 cites W2105969273 @default.
• W2020180938 cites W2111162768 @default.
• W2020180938 cites W2137814074 @default.
• W2020180938 cites W2152939220 @default.
• W2020180938 cites W2168558947 @default.
• W2020180938 doi "https://doi.org/10.1016/j.ijrobp.2011.06.1963" @default.
• W2020180938 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22079735" @default.
• W2020180938 hasPublicationYear "2012" @default.
• W2020180938 type Work @default.
• W2020180938 sameAs 2020180938 @default.
• W2020180938 citedByCount "127" @default.
• W2020180938 countsByYear W20201809382012 @default.
• W2020180938 countsByYear W20201809382013 @default.
• W2020180938 countsByYear W20201809382014 @default.
• W2020180938 countsByYear W20201809382015 @default.
• W2020180938 countsByYear W20201809382016 @default.
• W2020180938 countsByYear W20201809382017 @default.
• W2020180938 countsByYear W20201809382018 @default.
• W2020180938 countsByYear W20201809382019 @default.
• W2020180938 countsByYear W20201809382020 @default.
• W2020180938 countsByYear W20201809382021 @default.
• W2020180938 countsByYear W20201809382022 @default.
• W2020180938 countsByYear W20201809382023 @default.
• W2020180938 crossrefType "journal-article" @default.
• W2020180938 hasAuthorship W2020180938A5012796164 @default.
• W2020180938 hasAuthorship W2020180938A5013581376 @default.
• W2020180938 hasAuthorship W2020180938A5028786618 @default.
• W2020180938 hasAuthorship W2020180938A5034765756 @default.
• W2020180938 hasAuthorship W2020180938A5041943880 @default.
• W2020180938 hasAuthorship W2020180938A5055965589 @default.
• W2020180938 hasAuthorship W2020180938A5058839299 @default.
• W2020180938 hasAuthorship W2020180938A5060222943 @default.
• W2020180938 hasAuthorship W2020180938A5064028169 @default.
• W2020180938 hasAuthorship W2020180938A5064307215 @default.
• W2020180938 hasAuthorship W2020180938A5072460259 @default.
• W2020180938 hasAuthorship W2020180938A5077763767 @default.
• W2020180938 hasAuthorship W2020180938A5085700191 @default.
• W2020180938 hasAuthorship W2020180938A5086483620 @default.
• W2020180938 hasAuthorship W2020180938A5089211608 @default.
• W2020180938 hasConcept C126322002 @default.
• W2020180938 hasConcept C141071460 @default.
• W2020180938 hasConcept C197934379 @default.
• W2020180938 hasConcept C2776256026 @default.
• W2020180938 hasConcept C2777714996 @default.
• W2020180938 hasConcept C2777793932 @default.
• W2020180938 hasConcept C2779134260 @default.
• W2020180938 hasConcept C2779524853 @default.
• W2020180938 hasConcept C2779920096 @default.
• W2020180938 hasConcept C43270747 @default.
• W2020180938 hasConcept C509974204 @default.
• W2020180938 hasConcept C71924100 @default.
• W2020180938 hasConcept C75603125 @default.
• W2020180938 hasConcept C90924648 @default.
• W2020180938 hasConceptScore W2020180938C126322002 @default.
• W2020180938 hasConceptScore W2020180938C141071460 @default.
• W2020180938 hasConceptScore W2020180938C197934379 @default.
• W2020180938 hasConceptScore W2020180938C2776256026 @default.
• W2020180938 hasConceptScore W2020180938C2777714996 @default.
• W2020180938 hasConceptScore W2020180938C2777793932 @default.
• W2020180938 hasConceptScore W2020180938C2779134260 @default.
• W2020180938 hasConceptScore W2020180938C2779524853 @default.
• W2020180938 hasConceptScore W2020180938C2779920096 @default.
• W2020180938 hasConceptScore W2020180938C43270747 @default.
• W2020180938 hasConceptScore W2020180938C509974204 @default.
• W2020180938 hasConceptScore W2020180938C71924100 @default.
• W2020180938 hasConceptScore W2020180938C75603125 @default.
• W2020180938 hasConceptScore W2020180938C90924648 @default.
• W2020180938 hasIssue "1" @default.
• W2020180938 hasLocation W20201809381 @default.

• next